Biomarkers of Osimertinib Response in Patients with Refractory, EGFR-T790M–positive Non–Small Cell Lung Cancer and Central Nervous System Metastases: The APOLLO Study

Ligang Xing,Yueyin Pan,Yuankai Shi,Yongqian Shu,Jifeng Feng,Wei Li,Lejie Cao,Lifeng Wang,Wei Gu,Yong Song,Puyuan Xing,Yutao Liu,Wen Gao,Jiuwei Cui,Nana Hu,Rutian Li,Hua Bao,Yang Shao,Jinming Yu

DOI: https://doi.org/10.1158/1078-0432.ccr-20-2081

IF: 13.801

2020-08-17

Clinical Cancer Research

Abstract:PURPOSE: Dynamic biomarker monitoring may inform pathways for treating <i>EGFR</i>-T790M-positive non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases with osimertinib. This study aimed to determine the efficacy and safety of osimertinib for real-world patients with <i>EGFR</i>-T790M NSCLC and CNS metastases and to explore potential circulating biomarkers of therapeutic response.PATIENTS AND METHODS: APOLLO (ClinicalTrials.gov registration: NCT02972333) was a prospective, single-arm, open-label trial which ran from January 2017 to April 2019. Eligible patients had confirmed <i>EGFR</i>-T790M-positive NSCLC, prior treatment with an EGFR-tyrosine kinase inhibitor, and CNS metastases. All enrolled patients received oral osimertinib 80 mg once daily until disease progression or intolerable toxicity. Primary outcome was overall progression-free survival (PFSo) and secondary outcomes included objective response rate (ORR) and adverse events (AE). Exploratory biomarker analysis involved collection of plasma and cerebrospinal fluid (CSF) samples for next-generation sequencing and drug penetration analysis.RESULTS: From January to September 2017, 38 patients were enrolled. After a median follow-up of 8.2 months (range, 0.07-15.6), 23 (60.5%) of 38 patients had disease progression or death. Median PFSo was 8.4 months [95% confidence interval (CI), 5.8-10.9]. Overall ORR was 39.4%. Twelve (31.6%) of 38 patients had ≥1 grade 3-4 AE. Median osimertinib CSF penetration rate was 31.7%. Patients with undetectable plasma <i>EGFR</i> mutations at week 6 had improved PFSo compared with those with detectable mutations (not reached vs. 4.5 months; 95% CI, 0.0-1.1; <i>P</i> &lt; 0.05).CONCLUSIONS: Osimertinib had potent activity against <i>EGFR</i>-T790M-positive NSCLC with CNS metastases. Dynamic monitoring of plasma <i>EGFR</i> may suffice for predicting clinical responses, mitigating the need for repeat CSF biopsy.<i>See related commentary by Marmarelis and Bauml, p. 6077</i>.

oncology

What problem does this paper attempt to address?

The problem that this paper aims to solve is to evaluate the efficacy of osimertinib in treating non - small - cell lung cancer (NSCLC) patients with EGFR - T790M mutation who are resistant to previous EGFR tyrosine kinase inhibitor (EGFR - TKI) treatment, especially in the case where these patients have central nervous system (CNS) metastases simultaneously. In addition, the study also explores the correlation between potential circulating biomarkers and treatment response to guide clinical practice.

Specifically, the study focuses on the following aspects:
1. **Efficacy and safety of osimertinib**: The efficacy of osimertinib in this specific patient group is measured by evaluating the overall progression - free survival (PFS), objective response rate (ORR) and disease control rate (DCR).
2. **Dynamic monitoring of biomarkers**: Plasma and cerebrospinal fluid samples of patients are collected for next - generation sequencing (NGS) to analyze the changes in EGFR mutation load and explore the relationship between these changes and progression - free survival.
3. **Penetration ability of osimertinib in CNS**: The concentration of osimertinib in cerebrospinal fluid and its relationship with clinical response are evaluated.

The main objective of the study is to determine the effectiveness and safety of osimertinib in treating EGFR - T790M - positive NSCLC patients with CNS metastases and to explore circulating biomarkers that may be used to predict treatment response. Through these studies, it is hoped to provide more effective treatment strategies and monitoring means for clinicians.